This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.


13Jan 2020

Back to News overview

Lisette Rozeman wins the Antoni van Leeuwenhoek Award

PhD student Lisette Rozeman has won the 2019 Antoni van Leeuwenhoek Award for her excellent research into immunotherapy for melanoma patients. She examined how doctors could use immunotherapy in even more effective ways to fight cancer in these patients.



'Lisette Rozeman's research will profoundly change the treatment of melanoma patients,' says her supervisor Christian Blank, internist-oncologist and researcher at the Netherlands Cancer Institute. In close cooperation with colleagues inside and outside the organisation, Rozeman completed no fewer than three clinical studies during her four-year research period. 'Her work is unique. Lots of researchers develop a research protocol but then fail to get the study launched.'

Agreeing on the logistics

So how did Rozeman manage to get her research study done? 'It's a team effort,' says Lisette Rozeman modestly. 'There's a lot more involved in a clinical research study than you'd think. Besides a comprehensive study protocol there are all kinds of things that have to be done before you can begin. For instance, you have to build a database and you have to decide how tissue samples are going to be processed and assessed. And you have to agree on the logistics with all kinds of specialists: when will patients be coming to the hospital? How many scans will be needed? When will the patient be operated?'

Don't get irritated

That means getting everyone onto the same page, something Rozeman is very good at. 'Almost everyone here is very busy. I think I get things done quickly because I value the work that everyone else does, and I let that show. And I'm very aware that I'm just one more researcher calling with questions and wanting everything to be arranged as quickly as possible for their own study. But if you stay positive, if you're not deterred by setbacks, and you don't get irritated - or don't show it, anyway - then you can get a lot done.'

Rozeman not only got her clinical research done from the organisational and scientific perspectives, but she also treated the patients. 'I'm grateful that I was able to combine science and patient care in my PhD - not just doing data analysis. After all, research like this is done for actual patients.'

Three clinical studies

Those patients appear to have gained real benefit from her work. Rozeman's research focused on immunotherapy, an approach that aims to direct the patient's immune system against cancer cells (see e.g. this film). Three clinical studies on which she worked showed that it could be feasible and beneficial to employ immunotherapy even before a surgeon removes the tumour.

But why would you want to do so in the first place? There are at least two good reasons. Firstly, the immune reaction can be invoked more strongly when the whole tumour, with all its variations, is still present in the body. Secondly, it is possible to clearly detect, in the removed tumour, whether cancer cells have been killed, and therefore whether the patient has reacted well to immunotherapy. It might even be the case that patients who react well to immunotherapy can keep their lymph glands: at present these are always removed. A third, nearly completed study (PRADO) will soon shed more light on this topic.

Back to the Netherlands Cancer Institute

Lisette Rozeman is currently training as an internist at UMC Utrecht and hopes to graduate at the end of 2020. She wants to specialise in oncology or haematology: 'I've been thinking about coming back to the Netherlands Cancer Institute, where I've worked with so much pleasure in recent years.' For the time being she is devoting one day a week there to research.

The Antoni van Leeuwenhoek Award

The Netherlands Cancer Institute awards the annual Antoni van Leeuwenhoek Award to its most talented young researcher. The award includes €6000, to be spent on new research. The Netherlands Cancer Institute wants to express its gratitude to NKI alumnus Professor Roel Nusse from Stanford University, for generously having offered to co-fund the award from 2019 onwards.

Share this page